{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T18:38:12Z","timestamp":1794854292150,"version":"4.9.1"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010318","name":"University of Manitoba","doi-asserted-by":"publisher","award":["44872"],"award-info":[{"award-number":["44872"]}],"id":[{"id":"10.13039\/100010318","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010318","name":"University of Manitoba","doi-asserted-by":"publisher","award":["47255"],"award-info":[{"award-number":["47255"]}],"id":[{"id":"10.13039\/100010318","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","award":["RGPIN-2023-04919"],"award-info":[{"award-number":["RGPIN-2023-04919"]}],"id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009395","name":"Cancercare Manitoba Foundation","doi-asserted-by":"publisher","award":["761020451"],"award-info":[{"award-number":["761020451"]}],"id":[{"id":"10.13039\/100009395","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000155","name":"Government of Canada Social Sciences and Humanities Research Council","doi-asserted-by":"publisher","award":["NFRFE-00479-2021"],"award-info":[{"award-number":["NFRFE-00479-2021"]}],"id":[{"id":"10.13039\/501100000155","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT-175226"],"award-info":[{"award-number":["PJT-175226"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.biopha.2026.119221","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T09:03:04Z","timestamp":1774861384000},"page":"119221","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Dose dependent paradoxical increases in DNA methylation, reductions in p16 expression, and changes in histone modifications in gastric cancer cells treated with DNMT inhibitors"],"prefix":"10.1016","volume":"198","author":[{"given":"Wenxia","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0767-2339","authenticated-orcid":false,"given":"Olufola O.","family":"Ige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Barzegar Behrooz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haziqa B.","family":"Kassim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8030-3961","authenticated-orcid":false,"given":"Thordur","family":"Hendrickson-Rebizant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Paetkau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4729-9970","authenticated-orcid":false,"given":"Emmanuel A.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1593-997X","authenticated-orcid":false,"given":"Meaghan J.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"Davie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6625-6717","authenticated-orcid":false,"given":"Ted M.","family":"Lakowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2026.119221_bib1","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1017\/S0029665118000150","article-title":"The role of DNA methylation in ageing and cancer","volume":"77","author":"Morgan","year":"2018","journal-title":"Proc. Nutr. Soc."},{"key":"10.1016\/j.biopha.2026.119221_bib2","doi-asserted-by":"crossref","DOI":"10.1100\/2012\/761909","article-title":"Genetic aspects of gastric cancer instability","volume":"2012","author":"Hudler","year":"2012","journal-title":"ScientificWorldJournal"},{"key":"10.1016\/j.biopha.2026.119221_bib3","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.cca.2013.05.002","article-title":"Gene methylation in gastric cancer","volume":"424","author":"Qu","year":"2013","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.biopha.2026.119221_bib4","doi-asserted-by":"crossref","first-page":"4632","DOI":"10.1200\/JCO.2004.07.151","article-title":"DNA methylation and cancer","volume":"22","author":"Das","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2026.119221_bib5","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nrg.2017.33","article-title":"TET-mediated active DNA demethylation: mechanism, function and beyond","volume":"18","author":"Wu","year":"2017","journal-title":"Nat. Rev. Genet"},{"key":"10.1016\/j.biopha.2026.119221_bib6","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/PPO.0000000000000278","article-title":"DNA methylation-targeted drugs","volume":"23","author":"Da Costa","year":"2017","journal-title":"Cancer J."},{"key":"10.1016\/j.biopha.2026.119221_bib7","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1016\/j.drudis.2019.08.006","article-title":"DNA methyltransferases: emerging targets for the discovery of inhibitors as potent anticancer drugs","volume":"24","author":"Yu","year":"2019","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.biopha.2026.119221_bib8","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1038\/s43018-021-00249-x","article-title":"Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia","volume":"2","author":"Pappalardi","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.biopha.2026.119221_bib9","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/s42003-022-03509-3","article-title":"Chromosome-specific retention of cancer-associated DNA hypermethylation following pharmacological inhibition of DNMT1","volume":"5","author":"Wiseman","year":"2022","journal-title":"Commun. Biol."},{"key":"10.1016\/j.biopha.2026.119221_bib10","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.str.2022.03.009","article-title":"Structural characterization of dicyanopyridine containing DNMT1-selective, non-nucleoside inhibitors","volume":"30","author":"Horton","year":"2022","journal-title":"Structure"},{"key":"10.1016\/j.biopha.2026.119221_bib11","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/07391102.2023.2199081","article-title":"Discovery of potent DNMT1 inhibitors against sickle cell disease using structural-based virtual screening, MM-GBSA and molecular dynamics simulation-based approaches","volume":"42","author":"Ala","year":"2024","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.biopha.2026.119221_bib12","doi-asserted-by":"crossref","DOI":"10.1093\/narcan\/zcad022","article-title":"GSK-3484862 targets DNMT1 for degradation in cells","volume":"5","author":"Chen","year":"2023","journal-title":"NAR Cancer"},{"key":"10.1016\/j.biopha.2026.119221_bib13","doi-asserted-by":"crossref","first-page":"6010","DOI":"10.1158\/1538-7445.AM2023-6010","article-title":"Targeting p16 epimutation during lung cancer progression for anticancer therapy","volume":"83","author":"Chen","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2026.119221_bib14","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.biopha.2026.119221_bib15","first-page":"1553","article-title":"Enhanced serum methylated p16 DNAs is associated with the progression of gastric cancer","volume":"7","author":"Wu","year":"2014","journal-title":"Int J. Clin. Exp. Pathol."},{"key":"10.1016\/j.biopha.2026.119221_bib16","first-page":"164","article-title":"Aberrant promoter hypermethylation of p16, survivin, and retinoblastoma in gastric cancer","volume":"118","author":"Guo","year":"2017","journal-title":"Bratisl. Lek. Listy"},{"key":"10.1016\/j.biopha.2026.119221_bib17","first-page":"169","article-title":"P16 hypermethylation contributes to the characterization of gene inactivation profiles in primary gastric cancer","volume":"10","author":"Ficorella","year":"2003","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.biopha.2026.119221_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12032-015-0525-y","article-title":"Aberrant gene promoter methylation of p16, FHIT, CRBP1, WWOX, and DLC-1 in Epstein\u2013Barr virus-associated gastric carcinomas","volume":"32","author":"He","year":"2015","journal-title":"Med. Oncol."},{"key":"10.1016\/j.biopha.2026.119221_bib19","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.3748\/wjg.14.2055","article-title":"p16 promoter hypermethylation: a useful serum marker for early detection of gastric cancer","volume":"14","author":"Abbaszadegan","year":"2008","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.biopha.2026.119221_bib20","first-page":"2477","article-title":"Detection of aberrant methylation as a tumor marker in serum of patients with gastric cancer","volume":"24","author":"Ichikawa","year":"2004","journal-title":"Anticancer Res"},{"key":"10.1016\/j.biopha.2026.119221_bib21","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1007\/s00535-007-2113-1","article-title":"Aberrant methylation of p16 predicts candidates for 5-fluorouracil-based adjuvant therapy in gastric cancer patients","volume":"42","author":"Mitsuno","year":"2007","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.biopha.2026.119221_bib22","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.3748\/wjg.v24.i26.2818","article-title":"Biomarkers of gastric cancer: current topics and future perspective","volume":"24","author":"Matsuoka","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.biopha.2026.119221_bib23","doi-asserted-by":"crossref","first-page":"5495","DOI":"10.1158\/0008-5472.CAN-05-2385","article-title":"DNA methylation changes after 5-aza-2\u2032-deoxycytidine therapy in patients with leukemia","volume":"66","author":"Yang","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2026.119221_bib24","doi-asserted-by":"crossref","first-page":"7086","DOI":"10.1158\/0008-5472.CAN-05-0695","article-title":"Characterization of DNA demethylation effects induced by 5-aza-2\u2032-deoxycytidine in patients with myelodysplastic syndrome","volume":"65","author":"Mund","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2026.119221_bib25","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1158\/1541-7786.MCR-12-0332","article-title":"Targeted inactivation of HDAC2 restores p16INK4a activity and exerts antitumor effects on human gastric cancer","volume":"11","author":"Kim","year":"2013","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.biopha.2026.119221_bib26","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.biopha.2013.01.004","article-title":"Decitabine, a DNA methyltransferases inhibitor, induces cell cycle arrest at G2\/M phase through p53-independent pathway in human cancer cells","volume":"67","author":"Shin","year":"2013","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.biopha.2026.119221_bib27","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/S0145-2126(03)00068-7","article-title":"Decitabine induces cell cycle arrest at the G1 phase via p21 WAF1 and the G2\/M phase via the p38 MAP kinase pathway","volume":"27","author":"Lavelle","year":"2003","journal-title":"Leuk. Res."},{"key":"10.1016\/j.biopha.2026.119221_bib28","first-page":"1221","article-title":"Promoter histone H3 lysine 9 di-methylation is associated with DNA methylation and aberrant expression of p16 in gastric cancer cells","volume":"22","author":"Meng","year":"2009","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.biopha.2026.119221_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0053313","article-title":"The specificity and patterns of staining in human cells and tissues of p16INK4a antibodies demonstrate variant antigen binding","volume":"8","author":"Sawicka","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2026.119221_bib30","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1349-7006.2006.00136.x","article-title":"Chemical genomic screening for methylation-silenced genes in gastric cancer cell lines using 5-aza-2\u2032-deoxycytidine treatment and oligonucleotide microarray","volume":"97","author":"Yamashita","year":"2006","journal-title":"Cancer Sci."},{"key":"10.1016\/j.biopha.2026.119221_bib31","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nri2526","article-title":"The role of TNF superfamily members in T-cell function and diseases","volume":"9","author":"Croft","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.biopha.2026.119221_bib32","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/s11274-020-02943-x","article-title":"Salmonella Typhimurium peptidyl-prolyl cis-trans isomerase C (PPIase C) plays a substantial role in protein folding to maintain the protein structure","volume":"36","author":"Kumawat","year":"2020","journal-title":"World J. Microbiol. Biotechnol."},{"key":"10.1016\/j.biopha.2026.119221_bib33","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1091\/mbc.e01-10-0094","article-title":"Purification and identification of secernin, a novel cytosolic protein that regulates exocytosis in mast cells","volume":"13","author":"Way","year":"2002","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.biopha.2026.119221_bib34","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/npp.2012.112","article-title":"DNA methylation and its basic function","volume":"38","author":"Moore","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopha.2026.119221_bib35","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1021\/acs.jproteome.8b00118","article-title":"Selective DOT1L, LSD1, and HDAC class I inhibitors reduce HOXA9 expression in MLL-AF9 rearranged leukemia cells, but dysregulate the expression of many histone-modifying enzymes","volume":"17","author":"Lillico","year":"2018","journal-title":"J. Proteome Res"},{"key":"10.1016\/j.biopha.2026.119221_bib36","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jprot.2015.12.018","article-title":"HDAC inhibitors induce global changes in histone lysine and arginine methylation and alter expression of lysine demethylases","volume":"133","author":"Lillico","year":"2016","journal-title":"J. Proteom."},{"key":"10.1016\/j.biopha.2026.119221_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2025.110639","article-title":"SET7\/9 exhibits sigmoidal kinetics on nucleosomes, hyperbolic kinetics on histones by an ordered sequential mechanism, and methylates lysine and arginine","volume":"301","author":"Ige","year":"2025","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2026.119221_bib38","doi-asserted-by":"crossref","first-page":"9281","DOI":"10.1038\/srep09281","article-title":"The hypomethylating agent Decitabine causes a paradoxical increase in 5-hydroxymethylcytosine in human leukemia cells","volume":"5","author":"Chowdhury","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2026.119221_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.991751","article-title":"Decitabine-induced DNA methylation-mediated transcriptomic reprogramming in human breast cancer cell lines; the impact of DCK overexpression","volume":"13","author":"Buocikova","year":"2022","journal-title":"Front. Pharm."},{"key":"10.1016\/j.biopha.2026.119221_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2019.00385","article-title":"DNMT inhibitors increase methylation in the cancer genome","volume":"10","author":"Giri","year":"2019","journal-title":"Front. Pharm."},{"key":"10.1016\/j.biopha.2026.119221_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1868-7083-5-3","article-title":"Pharmacokinetic and pharmacodynamic analysis of 5-aza-2\u2032- deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy","volume":"5","author":"Karahoca","year":"2013","journal-title":"Clin. Epigenetics"},{"key":"10.1016\/j.biopha.2026.119221_bib42","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s00280-007-0531-7","article-title":"Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)","volume":"61","author":"Cashen","year":"2008","journal-title":"Cancer Chemother. Pharm."},{"key":"10.1016\/j.biopha.2026.119221_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2023.189066","article-title":"Epigenetic therapy: Research progress of decitabine in the treatment of solid tumors","volume":"1879","author":"Ye","year":"2024","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.biopha.2026.119221_bib44","doi-asserted-by":"crossref","unstructured":"G. Garcia-Manero, E.A. Griffiths, D.P. Steensma, G.J. Roboz, R. Wells, J. Mccloskey, O. Odenike, A.E. Dezern, K. Yee, L. Busque, C. O\u2019connell, L.C. Michaelis, J. Brandwein, H. Kantarjian, A. Oganesian, M. Azab, M.R. Savona, Oral cedazuridine\/decitabine for MDS and CMML: a phase 2 pharmacokinetic\/pharmacodynamic randomized crossover study, 2020. \u3008http:\/\/ashpublications.org\/blood\/article-pdf\/136\/6\/674\/1750722\/bloodbld2019004143.pdf\u3009.","DOI":"10.1182\/blood.2019004143"},{"key":"10.1016\/j.biopha.2026.119221_bib45","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.canlet.2014.08.010","article-title":"Decitabine, a new star in epigenetic therapy: The clinical application and biological mechanism in solid tumors","volume":"354","author":"Nie","year":"2014","journal-title":"Cancer Lett."},{"key":"10.1016\/j.biopha.2026.119221_bib46","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/sj.cr.7290222","article-title":"Epigenetic modification regulates both expression of tumor-associated genes and cell cycle progressing in human colon cancer cell lines: Colo-320 and SW1116","volume":"14","author":"Fang","year":"2004","journal-title":"Cell Res"},{"key":"10.1016\/j.biopha.2026.119221_bib47","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.dnarep.2016.04.008","article-title":"Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage","volume":"42","author":"Karimian","year":"2016","journal-title":"DNA Repair (Amst. )"},{"key":"10.1016\/j.biopha.2026.119221_bib48","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/366704a0","article-title":"A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D\/CDK4","volume":"366","author":"Serrano","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2026.119221_bib49","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15424","article-title":"Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies","volume":"8","author":"San Jos\u00e9-En\u00e9riz","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2026.119221_bib50","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1038\/s43018-021-00271-z","article-title":"The next generation of DNMT inhibitors","volume":"2","author":"Mehdipour","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.biopha.2026.119221_bib51","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.490.490","article-title":"The role of DNA damage\/stress response pathways in the mechanism of action of decitabine","volume":"112","author":"Ibanez","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2026.119221_bib52","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1128\/MCB.01799-07","article-title":"DNA methylation inhibitor 5-Aza-2\u2032-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B","volume":"28","author":"Palii","year":"2008","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.biopha.2026.119221_bib53","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gku775","article-title":"Quantitative determination of decitabine incorporation into DNA and its effect on mutation rates in human cancer cells","volume":"42","author":"\u00d6z","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.biopha.2026.119221_bib54","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/ijc.20797","article-title":"5-Aza-2\u2032-deoxycytidine induces p21WAF expression by demethylation of p73 leading to p53-independent apoptosis in myeloid leukemia","volume":"114","author":"Schmelz","year":"2005","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.biopha.2026.119221_bib55","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.leukres.2005.05.010","article-title":"5-Aza-2\u2032-deoxycytidine (decitabine) can relieve p21WAF1 repression in human acute myeloid leukemia by a mechanism involving release of histone deacetylase 1 (HDAC1) without requiring p21WAF1 promoter demethylation","volume":"30","author":"Scott","year":"2006","journal-title":"Leuk. Res."},{"key":"10.1016\/j.biopha.2026.119221_bib56","doi-asserted-by":"crossref","first-page":"7058","DOI":"10.3390\/ijms23137058","article-title":"Revisiting the function of p21CDKN1A in DNA repair: the influence of protein interactions and stability","volume":"23","author":"Ticli","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119221_bib57","unstructured":"S.C. Barranco, C.M. Townsend, C. Gasarteli, B.G. Macik, N.L. Burger, W.R. Boerwinkle, W.K. Gourley, Establishment and Characterization of an in Vitro Model System for Human Adenocarcinoma of the Stomach1, 1983. \u3008http:\/\/aacrjournals.org\/cancerres\/article-pdf\/43\/4\/1703\/2415330\/cr0430041703.pdf\u3009."},{"key":"10.1016\/j.biopha.2026.119221_bib58","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/ijc.31304","article-title":"Forty-nine gastric cancer cell lines with integrative genomic profiling for development of c-MET inhibitor","volume":"143","author":"Kim","year":"2018","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.biopha.2026.119221_bib59","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1080\/03602532.2018.1437446","article-title":"Effects of 5-Aza-2\u2032-deoxycytidine (decitabine) on gene expression","volume":"50","author":"Seelan","year":"2018","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.biopha.2026.119221_bib60","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12014-016-9115-z","article-title":"Quantitative proteomic analysis of histone modifications in decitabine sensitive and resistant leukemia cell lines","volume":"13","author":"Zhang","year":"2016","journal-title":"Clin. Proteom."},{"key":"10.1016\/j.biopha.2026.119221_bib61","doi-asserted-by":"crossref","first-page":"5166","DOI":"10.1158\/1078-0432.CCR-24-1166","article-title":"Epigenome reprogramming through H3K27 and H3K4 trimethylation as a resistance mechanism to DNA methylation inhibition in BRAFV600E-mutated colorectal cancer","volume":"30","author":"Lee","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2026.119221_bib62","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/5047","article-title":"Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer","volume":"21","author":"Cameron","year":"1999","journal-title":"Nat. Genet"},{"key":"10.1016\/j.biopha.2026.119221_bib63","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41420-024-01895-7","article-title":"Dual inhibitors of DNMT and HDAC induce viral mimicry to induce antitumour immunity in breast cancer","volume":"10","author":"Huang","year":"2024","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.biopha.2026.119221_bib64","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/s41392-023-01626-x","article-title":"Human endogenous retroviruses as epigenetic therapeutic targets in TP53-mutated diffuse large B-cell lymphoma","volume":"8","author":"Fang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.biopha.2026.119221_bib65","first-page":"6456","article-title":"Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2\u2019-deoxycytidine","volume":"62","author":"Nguyen","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2026.119221_bib66","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1038\/s41388-022-02404-9","article-title":"DNMT1-mediated epigenetic silencing of TRAF6 promotes prostate cancer tumorigenesis and metastasis by enhancing EZH2 stability","volume":"41","author":"Li","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2026.119221_bib67","doi-asserted-by":"crossref","first-page":"4313","DOI":"10.1093\/nar\/gkq187","article-title":"Targeting of 5-aza-2\u2019-deoxycytidine residues by chromatin-associated DNMT1 induces proteasomal degradation of the free enzyme","volume":"38","author":"Patel","year":"2010","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.biopha.2026.119221_bib68","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/978-1-0716-2376-3_10","article-title":"Enzyme-linked immunosorbent assay (ELISA)","volume":"2508","author":"Tabatabaei","year":"2022","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.biopha.2026.119221_bib69","doi-asserted-by":"crossref","first-page":"429","DOI":"10.4103\/1947-2714.100998","article-title":"Western blot: technique, theory, and trouble shooting","volume":"4","author":"Mahmood","year":"2012","journal-title":"N. Am. J. Med. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2026.119221_bib70","doi-asserted-by":"crossref","DOI":"10.4143\/crt.2005.37.1.1","article-title":"Biology of SNU cell lines","volume":"37","author":"Ku","year":"2005","journal-title":"Cancer Res. Treat."},{"key":"10.1016\/j.biopha.2026.119221_bib71","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.prp.2005.01.002","article-title":"Correlation between DNA alterations and p53 and p16 protein expression in cancer cell lines","volume":"201","author":"Murai","year":"2005","journal-title":"Pathol. Res. Pr."},{"key":"10.1016\/j.biopha.2026.119221_bib72","article-title":"Activation of SIRT6 by DNA hypomethylating agents and clinical consequences on combination therapy in leukemia","volume":"10","author":"Carraway","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2026.119221_bib73","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1038\/s41598-017-04406-0","article-title":"Epigenetic targeting drugs potentiate chemotherapeutic effects in solid tumor therapy","volume":"7","author":"Li","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2026.119221_bib74","doi-asserted-by":"crossref","first-page":"6305","DOI":"10.1158\/0008-5472.CAN-04-2957","article-title":"Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases","volume":"65","author":"Brueckner","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2026.119221_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114320","article-title":"p16 methylation is a potential predictive marker for abemaciclib sensitivity in gastric cancer","volume":"183","author":"Bae","year":"2021","journal-title":"Biochem Pharm."},{"key":"10.1016\/j.biopha.2026.119221_bib76","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/1471-2407-10-240","article-title":"Identification of valid reference genes for gene expression studies of human stomach cancer by reverse transcription-qPCR","volume":"10","author":"Rho","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.biopha.2026.119221_bib77","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.aca.2011.07.014","article-title":"High-throughput and cost-effective global DNA methylation assay by liquid chromatography-mass spectrometry","volume":"703","author":"Li","year":"2011","journal-title":"Anal. Chim. Acta"},{"key":"10.1016\/j.biopha.2026.119221_bib78","doi-asserted-by":"crossref","DOI":"10.1080\/15592294.2024.2322386","article-title":"Novel DNA methylation changes in mouse lungs associated with chronic smoking","volume":"19","author":"Onuzulu","year":"2024","journal-title":"Epigenetics"},{"key":"10.1016\/j.biopha.2026.119221_bib79","doi-asserted-by":"crossref","first-page":"L552","DOI":"10.1152\/ajplung.00192.2023","article-title":"Early-life exposure to cigarette smoke primes lung function and DNA methylation changes at Cyp1a1 upon exposure later in life","volume":"325","author":"Onuzulu","year":"2023","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226002544?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226002544?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T02:31:33Z","timestamp":1779244293000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226002544"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":79,"alternative-id":["S0753332226002544"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119221","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dose dependent paradoxical increases in DNA methylation, reductions in p16 expression, and changes in histone modifications in gastric cancer cells treated with DNMT inhibitors","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119221","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119221"}}